Literature DB >> 21549515

Impact of gender, partner status, and race on locoregional failure and overall survival in head and neck cancer patients in three radiation therapy oncology group trials.

Thomas J Dilling1, Kyounghwa Bae, Rebecca Paulus, Deborah Watkins-Bruner, Adam S Garden, Arlene Forastiere, K Kian Ang, Benjamin Movsas.   

Abstract

PURPOSE: We investigated the impact of race, in conjunction with gender and partner status, on locoregional control (LRC) and overall survival (OS) in three head and neck trials conducted by the Radiation Therapy Oncology Group (RTOG). METHODS AND MATERIALS: Patients from RTOG studies 9003, 9111, and 9703 were included. Patients were stratified by treatment arms. Covariates of interest were partner status (partnered vs. non-partnered), race (white vs. non-white), and sex (female vs. male). Chi-square testing demonstrated homogeneity across treatment arms. Hazards ratio (HR) was used to estimate time to event outcome. Unadjusted and adjusted HRs were calculated for all covariates with associated 95% confidence intervals (CIs) and p values.
RESULTS: A total of 1,736 patients were analyzed. Unpartnered males had inferior OS rates compared to partnered females (adjusted HR = 1.22, 95% CI, 1.09-1.36), partnered males (adjusted HR = 1.20, 95% CI, 1.09-1.28), and unpartnered females (adjusted HR = 1.20, 95% CI, 1.09-1.32). White females had superior OS compared with white males, non-white females, and non-white males. Non-white males had inferior OS compared to white males. Partnered whites had improved OS relative to partnered non-white, unpartnered white, and unpartnered non-white patients. Unpartnered males had inferior LRC compared to partnered males (adjusted HR = 1.26, 95% CI, 1.09-1.46) and unpartnered females (adjusted HR = 1.30, 95% CI, 1.05-1.62). White females had LRC superior to non-white males and females. White males had improved LRC compared to non-white males. Partnered whites had improved LRC compared to partnered and unpartnered non-white patients. Unpartnered whites had improved LRC compared to unpartnered non-whites.
CONCLUSIONS: Race, gender, and partner status had impacts on both OS and locoregional failure, both singly and in combination.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21549515      PMCID: PMC3170693          DOI: 10.1016/j.ijrobp.2011.01.013

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  35 in total

1.  The importance of marital and socioeconomic status in incidence and survival of prostate cancer. An analysis of complete Norwegian birth cohorts.

Authors:  S Harvei; O Kravdal
Journal:  Prev Med       Date:  1997 Sep-Oct       Impact factor: 4.018

2.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.

Authors:  Lisa Licitra; Federica Perrone; Paolo Bossi; Simona Suardi; Luigi Mariani; Raffaella Artusi; Maria Oggionni; Chiara Rossini; Giulio Cantù; Massimo Squadrelli; Pasquale Quattrone; Laura D Locati; Cristiana Bergamini; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

3.  Marital status as an independent predictor of event-free survival of patients with heart failure.

Authors:  Misook L Chung; Terry A Lennie; Barbara Riegel; Jia-Rong Wu; Rebecca L Dekker; Debra K Moser
Journal:  Am J Crit Care       Date:  2009-11       Impact factor: 2.228

4.  Disparate outcomes in patients with colorectal cancer: effect of race on long-term survival.

Authors:  L James Wudel; William C Chapman; Yu Shyr; Mark Davidson; Anita Jeyakumar; Selwyn O Rogers; Tara Allos; Steven C Stain
Journal:  Arch Surg       Date:  2002-05

5.  Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.

Authors:  Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri
Journal:  J Clin Oncol       Date:  2006-01-09       Impact factor: 44.544

6.  Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer.

Authors:  Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

7.  Inequalities in survival from colorectal cancer: a comparison of the impact of deprivation, treatment, and host factors on observed and cause specific survival.

Authors:  H Wrigley; P Roderick; S George; J Smith; M Mullee; J Goddard
Journal:  J Epidemiol Community Health       Date:  2003-04       Impact factor: 3.710

8.  Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.

Authors:  A S Garden; J Harris; E E Vokes; A A Forastiere; J A Ridge; C Jones; E M Horwitz; B S Glisson; L Nabell; J S Cooper; W Demas; E Gore
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

9.  The impact of health insurance status on the survival of patients with head and neck cancer.

Authors:  Joseph Kwok; Scott M Langevin; Athanassios Argiris; Jennifer R Grandis; William E Gooding; Emanuela Taioli
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

10.  Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma.

Authors:  Farah Y Ghori; Danielle R Gutterman-Litofsky; Amin Jamal; Sai-Ching J Yeung; Ridha Arem; Steven I Sherman
Journal:  Thyroid       Date:  2002-11       Impact factor: 6.568

View more
  7 in total

1.  The "rocky treatment course": identifying a high-risk subgroup of head and neck cancer patients for supportive interventions.

Authors:  Horia Vulpe; Janet Ellis; Shao Hui Huang; Eshetu G Atenafu; Raymond W Jang; Gary Rodin; Jolie Ringash
Journal:  Support Care Cancer       Date:  2016-11-04       Impact factor: 3.603

2.  Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma.

Authors:  Brian M Lin; Hao Wang; Gypsyamber D'Souza; Zhe Zhang; Carole Fakhry; Andrew W Joseph; Virginia E Drake; Giuseppe Sanguineti; William H Westra; Sara I Pai
Journal:  Cancer       Date:  2013-07-16       Impact factor: 6.860

3.  Race disparities attributed to volumetric tumor burden in patients with head and neck cancer treated with radiotherapy.

Authors:  Muhammad M Qureshi; Paul B Romesser; Abdallah Ajani; Lisa A Kachnic; Scharukh Jalisi; Minh Tam Truong
Journal:  Head Neck       Date:  2015-06-16       Impact factor: 3.147

Review 4.  Head and neck cancer management and cancer stem cells implication.

Authors:  Osama A Elkashty; Ramy Ashry; Simon D Tran
Journal:  Saudi Dent J       Date:  2019-06-10

5.  Socioeconomic and Other Demographic Disparities Predicting Survival among Head and Neck Cancer Patients.

Authors:  Seung Hee Choi; Jeffrey E Terrell; Karen E Fowler; Scott A McLean; Tamer Ghanem; Gregory T Wolf; Carol R Bradford; Jeremy Taylor; Sonia A Duffy
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

6.  Impact of Marital Status on Tumor Stage at Diagnosis and on Survival in Male Breast Cancer.

Authors:  Orimisan Samuel Adekolujo; Shourya Tadisina; Ujwala Koduru; Jill Gernand; Susan Jane Smith; Radhika Ramani Kakarala
Journal:  Am J Mens Health       Date:  2016-09-29

7.  Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis.

Authors:  Eve LoCastro; Ramesh Paudyal; Yousef Mazaheri; Vaios Hatzoglou; Jung Hun Oh; Yonggang Lu; Amaresha Shridhar Konar; Kira Vom Eigen; Alan Ho; James R Ewing; Nancy Lee; Joseph O Deasy; Amita Shukla-Dave
Journal:  Tomography       Date:  2020-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.